ITC Issues Exclusion Order on Plant-Derived Recombinant Human Serum Albumins
The International Trade Commission has issued a limited exclusion order blocking the importation of plant-derived recombinant human serum albumins (rHSA) (ITC Inv. No. 337-TA-1238). The case began with a December 2020 complaint by Ventria Bioscience that alleged infringement of two…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
of its patents by Wuhan Healthgen and its domestic distributors (see 2012230089). The investigation found that only one of the patents, covering improvements to cell culture growth methods, was infringed upon. Administrative Law Judge MaryJoan McNamara in April found a violation and recommended a limited exclusion order and a cease and desist order against Wuhan Healthgen. In June, the commission determined to review the final initial determination in its entirety (see 2206090007) and voted to extend the investigation beyond its Aug. 8 completion date before finally ruling on Sept. 12. "This case epitomizes the importance of the ITC, particularly for small but innovative American manufacturers seeking protection from unfair foreign competition," said Beau Jackson of Husch Blackwell, attorney for Ventria.